Vor Biopharma Inc. (VOR) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Vor Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing telitacicept, a dual-target recombinant fusion protein for autoimmune diseases. The company holds exclusive rights to develop and commercialize telitacicept outside of Greater China via a license agreement with RemeGen Co., Ltd. As of June 30, 2026, the company is conducting global Phase 3 clinical trials for telitacicept in generalized myasthenia gravis (gMG) and Sjögren's disease (SjD).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(62.8) million | $(282.4) million | $(1,606.2) million |
| Diluted EPS | $(1.16) | $(5.80) | $(256.88) |
| Operating Expenses | $47.9 million | $83.0 million | $307.6 million |
| Cash & Cash Equivalents | As of June 30, 2026: $107.9 million | ||
| Marketable Securities | |||
| Total Liquidity | As of June 30, 2026: $466.1 million | ||
| Warrant Liabilities | As of June 30, 2026: $653.9 million | ||
| Accumulated Deficit | As of June 30, 2026: $(1,435.4) million |
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: The net loss for the six months ended June 30, 2026, was $282.4 million, a decrease of $1.3 billion compared to the prior year period. This improvement is primarily driven by a reduction in the non-cash "Change in fair value of warrant liabilities" expense, which decreased from $1.3 billion in YTD 2025 to $207.7 million in YTD 2026.
- Operating Expense Shift: Total operating expenses decreased by $224.6 million year-over-year. This is largely due to the absence of the $222.6 million upfront charge for the Telitacicept License Agreement recognized in Q2 2025. Conversely, General and Administrative (G&A) expenses increased by $20.1 million, driven by higher stock-based compensation and commercial preparation costs.
- Liquidity Position: Cash and cash equivalents decreased from $396.5 million at year-end 2025 to $107.9 million at June 30, 2026, while marketable securities increased significantly to $358.3 million. The company utilized cash for operating activities ($63.6 million) and investing activities ($299.8 million, primarily purchases of marketable securities).
- Capital Raises: The company raised $74.9 million in net proceeds from a private placement in March 2026. Additionally, subsequent to the reporting period, the company sold shares under its At-the-Market (ATM) facility for gross proceeds of $48.9 million.
Guidance, Outlook, and Risks
- Cash Runway: Management expects existing cash, cash equivalents, and marketable securities ($466.1 million as of June 30, 2026), combined with subsequent ATM proceeds, to fund operations into early 2029.
- Clinical Outlook: Topline data for the global Phase 3 gMG trial is anticipated in the first half of 2027. The Phase 3 SjD trial began dosing in March 2026.
- Key Risks:
- Dependency on Telitacicept: The company's success is entirely dependent on the development and commercialization of this single product candidate.
- Need for Additional Capital: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding.
- Warrant Liability Volatility: The company has significant warrant liabilities ($653.9 million) classified as liabilities, causing substantial non-cash volatility in net loss based on stock price fluctuations.
- Third-Party Reliance: The company relies on RemeGen for data from trials in Greater China and third-party manufacturers for supply.
- Regulatory Status Change: The company will cease to qualify as an "emerging growth company" or "smaller reporting company" after December 31, 2026, becoming a large accelerated filer in 2027, which will increase compliance costs.
Investor Verification Checklist
- Verify the cash runway calculation and assumptions regarding future operating expenses, particularly as Phase 3 trials progress.
- Monitor the fair value of warrant liabilities, as fluctuations in the stock price will continue to create significant non-cash volatility in reported net loss.
- Confirm the enrollment rates and timelines for the global Phase 3 trials in gMG and SjD, as delays could impact the 2027 data readout.
- Review the terms of the license agreement with RemeGen regarding milestone payments and royalty obligations, which could impact future cash flows upon approval.
- Assess the impact of the upcoming transition to large accelerated filer status on future compliance costs and internal control requirements.